BioStock: CombiGene headhunts again
With experience from Medical Affairs at MERCK and early drug development at Karo Bio, a solid background in research from a doctoral thesis at Karolinska Institutet and postdoctoral research at Mount Sinai School of Medicine in New York, Pernilla Fagergren chose to join the Swedish gene therapy company CombiGene. In her new role as Clinical Project Manager, she will be responsible for the company’s first clinical study in epilepsy. Pernilla talks to BioStock about the challenges, before the Phase I study can begin next year.
Read the full interview with Pernilla Fagergren at biostock.se:
This is a pressrelease from BioStock - Connecting Innovation & Capital. https://www.biostock.se/